# US 11,065,273 B2 · Treatment and prevention of alzheimer's disease (AD)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,065,273 B2
- Document ID: US11065273B2
- Status: Granted
- Kind: B2
- Application number: 15/307,246
- Filed: 2015-04-29
- Published: 2017-02-23
- Granted: 2021-07-20
- Earliest claimed: 2014-04-29
- Assignees: Affiris AG
- Applicants: Affiris AG
- Inventors: Markus Mandler; Achim Schneeberger; Wolfgang Zauner; Arne Von Bonin; Frank Mattner; Walter Schmidt
- Web page: https://patentgrep.com/patent/US11065273B2

## CPC

- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/08: Oxides; Hydroxides
- A61K 33/42: Phosphorus; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with β-amyloid deposition, preferably AD.

## Claims

### Claim 1

A method for reducing the severity of a dementia associated with β-amyloid deposition comprising administering to a subject in need thereof a composition comprising an effective amount of at least one aluminium salt as the sole active ingredient in a dose form of an amount exceeding an amount prescribed in the US general biological products standards of 21 C.F.R. 610.15, as of Apr. 2013.

### Claim 2 (depends on 1)

The method of claim 1, wherein said dementia associated with β-amyloid deposition is Alzheimer's Disease (AD).

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one aluminium salt comprises aluminium oxyhydroxide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the aluminium salt has the general formula MeaAlb3+Anc−nH2O, wherein
Me+ is Na+, K+, Li+, Rb+, Cs+ or NH4+;
An is PO43−, SO42−, O(OH)3−, O2− or OH−;
a is 0, 1, 2, or 3;
b is 1 or 2;
c is 1, 2, 3, 4, 5, or 6; and
n is 0 to 48.

### Claim 5 (depends on 1)

The method of claim 1, wherein the aluminium salt is at least one of aluminium hydroxide, aluminium oxyhydroxide, aluminium phosphate, or aluminium sulphate.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition further comprises at least one pharmaceutically acceptable excipient(s).

### Claim 7 (depends on 1)

The method of claim 1, wherein the aluminium salt is an aluminium oxyhydroxide suspension.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition further comprises at least one of thiomersal, a stabilisator, a detergent, an antioxidant, a complexing agent for monovalent metal ion, a complexing agent for a divalent metal ion, sugar, sugar alcohol, or a buffer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is a suspension having a pH ranging from 4 to 10.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administrating is subcutaneously, intranodally, intradermally, or intramuscularly.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is administered at least once monthly for at least two months.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is administered at least once monthly for at least six months.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered at least twice a month for at least six months.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition is administered at least twice a month for at least twelve months.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition is administered at least twice a month for at least twenty four months.